Source: Pharmacy Times articles
Adding daratumumab improved minimal residual disease (MRD) negativity rates, leading to superior progression-free survival (PFS).
Read More
Recent Content
- Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
- Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma
- Quadruplet Regimen Preferable to Triplets in Multiple Myeloma
- Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
- Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
- Daratumumab regimen improves survival in transplant-ineligible multiple myeloma
- Communication is Key When Transitioning Multiple Myeloma Care
- Long-Term Follow-Up Data from the CASSIOPEIA Trial Show Continued MRD, PFS Benefit in Multiple Myeloma
- A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab
- Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma